-+ 0.00%
-+ 0.00%
-+ 0.00%

EU Medicines Agency Panel Backs SciencePharma's NovoRapid Biosimilar for Diabetes

MT Newswires·11/13/2026 07:13:00
Listen to the news
07:13 AM EST, 11/13/2026 (MT Newswires) -- The European Medicines Agency's Committee for Medicinal Products for Human Use recommended granting marketing authorization to SciencePharma's insulin aspart drug Garzulys, a biosimilar to Novo Nordisk's (NOVO-B.CO) NovoRapid. Garzulys is intended to treat diabetes mellitus in adults, adolescents and children aged one year and above, according to a Friday notice. The committee's positive opinion is based on data showing that Garzulys has comparable quality, safety and efficacy to NovoRapid, which was authorized in the EU in September 1999. The drug is subject to a final marketing authorization decision by the European Commission.